These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3208795)

  • 1. On the pharmacokinetics and metabolism of propiverine in man.
    Haustein KO; Hüller G
    Eur J Drug Metab Pharmacokinet; 1988; 13(2):81-90. PubMed ID: 3208795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the metabolic pattern of propiverine in urine after single administration.
    Hüller G; Haustein KO; Scheithauer S
    Pharmazie; 1988 Feb; 43(2):91-5. PubMed ID: 3393594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent.
    Haustein KO; Fritzsche K
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):392-5. PubMed ID: 6117520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
    Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
    Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
    Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
    J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of propiverine in patients with fatty liver disease.
    Siepmann M; Nokhodian A; Thümmler D; Kirch W
    Eur J Clin Pharmacol; 1998; 54(9-10):767-71. PubMed ID: 9923582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine.
    Siegmund W; Siegert J; Richter K; Schnabel F; Feustel C; Kirch W
    J Clin Pharmacol; 2012 May; 52(5):681-90. PubMed ID: 21551317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics.
    Yamada S; Ito Y; Taki Y; Seki M; Nanri M; Yamashita F; Morishita K; Komoto I; Yoshida K
    Drug Metab Dispos; 2010 Aug; 38(8):1314-21. PubMed ID: 20483954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms.
    May K; Westphal K; Giessmann T; Wegner D; Adam U; Lerch MM; Oertel R; Warzok RW; Weitschies W; Braeter M; Siegmund W
    J Clin Pharmacol; 2008 May; 48(5):570-9. PubMed ID: 18319360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatobiliary elimination of bendamustin (Cytostasan) in rats.
    Bezek S; Scasnár V; Trnovec T; Grupe R
    Pharmazie; 1991 Nov; 46(11):810-1. PubMed ID: 1811234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.
    Setnikar I; Rovati LC
    Arzneimittelforschung; 2001 Sep; 51(9):699-725. PubMed ID: 11642003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and metabolism of indeloxazine hydrochloride, a cerebral activator, in rats.
    Kamimura H; Enjoji Y; Sasaki H; Kawai R; Kaniwa H; Niigata K; Kageyama S
    Xenobiotica; 1987 Jun; 17(6):645-58. PubMed ID: 3630201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
    Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
    Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man.
    Scherling D; Karl W; Ahr G; Ahr HJ; Wehinger E
    Arzneimittelforschung; 1988 Aug; 38(8):1105-10. PubMed ID: 2973788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and metabolism of [14C]-haloperidol in rats.
    Miyazaki H; Matsunaga Y; Nambu K; Oh-e Y; Yoshida K; Hashimoto M
    Arzneimittelforschung; 1986 Mar; 36(3):443-52. PubMed ID: 3707663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and disposition of carvedilol in humans.
    Neugebauer G; Akpan W; von Möllendorff E; Neubert P; Reiff K
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S85-8. PubMed ID: 2454375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and metabolism of a novel diurea inhibitor of acyl CoA: cholesterol acyltransferase (YM17E) in the rat and dog.
    Uchida T; Nakamura E; Usui T; Imasaki H; Kawakami R; Watanabe T; Higuchi S
    Xenobiotica; 1994 Dec; 24(12):1223-36. PubMed ID: 7771109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.